about
Splenic marginal zone lymphoma with or without villous lymphocytes. Hematologic findings and outcomes in a series of 57 patients.Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele.Two cases of q-Fever in hairy cell leukemia.Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.Treatment of acute promyelocytic leukemia with gemtuzumab ozogamicin.The biology of acute promyelocytic leukemia and its impact on diagnosis and treatment.Acute promyelocytic leukemia: recent advances in diagnosis and management.Role of gamma-glutamyl cysteine synthetase (gamma-GCS) gene expression as marker of drug sensitivity in acute myeloid leukemias.NPM1 gene deletions in myelodysplastic syndromes with 5q- and complex karyotype.Molecular characterization of paediatric idiopathic hypereosinophilia.Are blood donors an adequate control group to ascertain HCV prevalence in non-Hodgkin's lymphoma patients.Higher frequency of HCV in patients with non-Hodgkin lymphoma: is it enough to suggest an association with B-cell NHL?Hepatitis B virus reactivation and alemtuzumab therapy.Long-lasting remission of primary hepatic lymphoma and hepatitis C virus infection achieved by the alpha-interferon treatment.Use of arsenic trioxide in secondary acute promyelocytic leukemia developing after treatment of multiple sclerosis with mitoxantrone.Identification of a potential "hotspot" DNA region in the RUNX1 gene targeted by mitoxantrone in therapy-related acute myeloid leukemia with t(16;21) translocation.Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia.Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes.CD20-selective inhibition of CD47-SIRPα “don't eat me” signaling with a bispecific antibody-derivative enhances the anticancer activity of daratumumab, alemtuzumab and obinutuzumab.Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib.Rapid detection of nucleophosmin (NPM1) mutations in acute myeloid leukemia by denaturing HPLC.Spontaneous apoptosis and proliferation detected by BCL-2 and CD71 proteins are important progression indicators within ZAP-70 negative chronic lymphocytic leukemia.Successful pregnancy after arsenic trioxide therapy for relapsed acute promyelocytic leukaemiaCancer cell-expressed SLAMF7 is not required for CD47-mediated phagocytosis
P50
Q33362814-08FD35CC-3106-444B-AA7B-17FB385E57D1Q33385124-5A954D6B-CE9D-4580-B1FD-A0F3151E119CQ34087110-64DBE5DA-81DC-4578-A063-A154080F7069Q34750640-53486D2F-578B-488F-B9E4-5980409B7318Q36430455-B070AB32-5AE1-42FA-84A1-9F050C8C91BEQ36662146-855890F9-69A3-4381-AAE8-26772A1A6817Q37240576-D9757746-1CD2-46B1-B6D0-31DF8F6B8A4CQ42485562-CF517721-E75D-4BB7-A798-55F1787789F3Q42724172-CD41A5E8-5AD7-463E-BD78-A2DA4F0E4541Q42855622-08343B34-8997-43D1-B03E-94EDA294F84FQ43039413-B60C3C86-CF8D-4764-8A33-CCD0461D25C5Q43041954-32F98FCB-2B59-48FE-A099-4E4D835EEC63Q45252401-7BA8218D-9633-4D70-A84D-DB9602961AC7Q45542080-CE34968E-7C2D-43FF-A5D1-B73E30AF7F0AQ45991047-001ECA00-8C53-4F59-9E1D-7C7B054E6D4BQ46234848-4D33890F-2C2B-47C6-9C1F-5ECFACBE2071Q46562604-F934AA58-519D-4966-A61D-E56DF9D8DDB2Q46586197-12515AE4-A2FB-4A97-9E88-B5E4F45711ACQ47114374-3EC5FF7D-384D-4A88-8716-41167BE18688Q54303081-F6281DC9-BCC2-4DC0-A6D4-B7997AF66BD8Q54634527-4AB074D8-BABE-4701-AAA7-C67D49FD62C4Q54704847-24794AF5-95A4-44A6-8727-F38E20FB0505Q56880895-F81391D4-274A-465C-9BC8-7EAD968BA3CCQ61804403-63701C7B-C894-4540-AB52-B9C0C7673427
P50
name
Emanuele Ammatuna
@ast
Emanuele Ammatuna
@en
Emanuele Ammatuna
@nl
type
label
Emanuele Ammatuna
@ast
Emanuele Ammatuna
@en
Emanuele Ammatuna
@nl
prefLabel
Emanuele Ammatuna
@ast
Emanuele Ammatuna
@en
Emanuele Ammatuna
@nl